Document Detail


Fibroblast growth factor 23 and the heart.
MedLine Citation:
PMID:  22531163     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Elevated serum levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23) are strongly associated with chronic kidney disease (CKD) progression and mortality, and are also independently associated with left ventricular hypertrophy, a major contributor to cardiovascular disease (CVD) and death in CKD patients. As FGF23 levels rise long before serum phosphate in CKD, FGF23 is a more sensitive biomarker of disordered phosphate metabolism and its associated renal and CVD toxicity.
RECENT FINDINGS: This review will address the novel possibility that FGF23 contributes directly to CVD in patients with CKD. We will summarize the basic principles of FGF-mediated signal transduction and review the current literature on effects of FGF family members on the heart as well as FGF23 signaling in 'classic' target cells, in order to flesh out the novelty underlying FGF23-induced cell signaling in the heart. By doing so we will speculate on why such a direct cardiac effect has not been described before, and suggest a novel target for pharmacological intervention.
SUMMARY: By demonstrating direct pathological effects of FGF23 on the heart, novel findings from a recent translational study reposition FGF23 from biomarker of risk, to mechanism of disease. Therefore the pharmacological interference with FGF23 and/or its cardiac receptor in CKD patients could be beneficial to prevent or treat CVD.
Authors:
Christian Faul
Related Documents :
7245473 - The myocardial depressant factor (mdf) in acute hemorrhagic pancreatitis.
21857143 - One-year cardiovascular event rates in japanese outpatients with myocardial infarction,...
2524993 - Thrombolytic therapy in acute myocardial infarction.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in nephrology and hypertension     Volume:  21     ISSN:  1473-6543     ISO Abbreviation:  Curr. Opin. Nephrol. Hypertens.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-01     Completed Date:  2012-10-03     Revised Date:  2013-05-02    
Medline Journal Info:
Nlm Unique ID:  9303753     Medline TA:  Curr Opin Nephrol Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  369-75     Citation Subset:  IM    
Affiliation:
Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. cfaul@med.miami.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Biological Markers / metabolism
Cardiovascular Diseases / blood,  etiology*,  metabolism,  pathology
Chronic Disease
Fibroblast Growth Factors / blood,  metabolism*
Glucuronidase / metabolism
Humans
Hypertrophy, Left Ventricular / etiology,  metabolism
Kidney Diseases / blood,  complications*,  metabolism
Myocardium / metabolism*,  pathology
Prognosis
Signal Transduction
Up-Regulation
Ventricular Remodeling
Chemical
Reg. No./Substance:
0/Biological Markers; 0/fibroblast growth factor 23; 62031-54-3/Fibroblast Growth Factors; EC 3.2.1.31/Glucuronidase; EC 3.2.1.31/klotho protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular imaging in chronic kidney disease.
Next Document:  Process technology for multi-enzymatic reaction systems.